Lytix Biopharma Feed

	Tid*
2024-11-19	-	Kvartalsrapport 2024-Q3
2024-08-29	-	Kvartalsrapport 2024-Q2
2024-05-30	-	Kvartalsrapport 2024-Q1
2024-04-25	-	Extra Bolagsstämma 2024
2024-04-19	-	X-dag ordinarie utdelning LYTIX 0.00 NOK
2024-04-18	-	Årsstämma
2024-02-29	-	Bokslutskommuniké 2023
2023-11-09	-	Kvartalsrapport 2023-Q3
2023-08-31	-	Kvartalsrapport 2023-Q2
2023-05-11	-	Kvartalsrapport 2023-Q1
2023-04-19	-	X-dag ordinarie utdelning LYTIX 0.00 NOK
2023-04-18	-	Årsstämma
2023-02-16	-	Bokslutskommuniké 2022
2022-11-17	-	Kvartalsrapport 2022-Q3
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-05-12	-	Kvartalsrapport 2022-Q1
2022-04-22	-	X-dag ordinarie utdelning LYTIX 0.00 NOK
2022-04-21	-	Årsstämma
2022-02-17	-	Bokslutskommuniké 2021

Land	Norge
Lista	Euronext Growth Oslo
Sektor	Hälsovård
Industri	Bioteknik

2024-12-17 15:53:15 Lytix Biopharma AS - Mandatory Notification of Trade - Share Lending by Closely Associated Party of a Primary Insider 5,82 NOK | -16,86%

2024-12-17 08:05:00 Lytix Biopharma AS: Key information relating to potential subsequent offering 5,82 NOK | -16,86%

2024-12-17 08:05:00 Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates 5,82 NOK | -16,86%

2024-12-17 08:00:00 Lytix Biopharma AS: Key information relating to potential subsequent offering 5,82 NOK | -16,86%

2024-12-17 08:00:00 Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates 5,82 NOK | -16,86%

2024-12-17 00:30:37 Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed 7,00 NOK | -2,78%

2024-12-17 00:27:04 Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed 7,00 NOK | -2,78%

2024-12-16 17:09:15 Lytix Biopharma AS: Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement 5,82 NOK | -16,86%

2024-12-16 17:04:06 Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid 5,82 NOK | -16,86%

2024-12-16 16:45:30 Lytix Biopharma - Lytix lanserer emisjon for småinvestorer via PrimaryBid og Nordnet, parallelt med en rettet emisjon 5,82 NOK | -16,86%

2024-12-16 16:45:30 Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement 5,82 NOK | -16,86%

2024-12-16 16:32:32 Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid 5,82 NOK | -16,86%

2024-11-26 12:54:00 LYTIX: Lytix Biopharma presents updated phase II results from skin cancer study (BCC) at the DNB Nordic Healthcare Conference 6,82 NOK | +8,60%

2024-11-21 15:48:15 Lytix Biopharma AS: Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion 6,40 NOK | +7,02%

2024-11-21 15:40:15 Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion 6,40 NOK | +7,02%

2024-11-19 07:05:00 Lytix Biopharma AS: Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization 5,84 NOK | -8,75%

2024-11-19 07:00:00 Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization 5,84 NOK | -8,75%

2024-11-12 10:33:58 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q3 2024 Results Presentation 6,82 NOK | -1,16%

2024-11-12 10:10:30 Lytix Biopharma: Invitation to Q3 2024 Results Presentation 6,82 NOK | -1,16%

2024-11-06 22:23:47 Lytix Biopharma AS: First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma 6,80 NOK | +12,96%

2024-11-06 22:23:47 Lytix Biopharma AS: Lovende fase II-studie i pasienter med tidligfase føflekkreft startet opp ved Radiumhospitalet - første pasient behandlet med Lytix' kreftbehandling 6,80 NOK | +12,96%

2024-11-06 13:34:54 Lovende fase II-studie i pasienter med tidligfase føflekkreft startet opp ved Radiumhospitalet - første pasient behandlet med Lytix' kreftbehandling 6,02 NOK | -5,94%

2024-11-06 13:34:54 First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma 6,02 NOK | -5,94%

2024-11-05 07:05:00 Lytix Biopharma AS: Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals 6,40 NOK | -13,04%

2024-11-05 07:05:00 Lytix Biopharma AS: Lytix Biopharma - Oppdatering fra lisensieringspartner Verrica Pharmaceuticals 6,40 NOK | -13,04%

2024-11-05 07:00:00 Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals 6,40 NOK | -13,04%

2024-11-05 07:00:00 Lytix Biopharma - Oppdatering fra lisensieringspartner Verrica Pharmaceuticals 6,40 NOK | -13,04%

2024-11-01 07:04:06 LYTIX: Financial calendar 7,22 NOK | -7,44%

2024-11-01 07:04:05 LYTIX: Finansiell kalender 7,22 NOK | -7,44%

2024-10-24 14:19:54 Lytix Biopharma AS: Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference 6,70 NOK | +9,84%

2024-10-24 14:11:48 LYTIX: Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference 6,70 NOK | +9,84%

2024-08-29 08:05:00 Lytix Biopharma AS: Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization 9,50 NOK | -7,32%

2024-08-29 08:00:00 Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization 9,50 NOK | -7,32%

2024-08-23 08:05:00 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q2 2024 Results Presentation 11,30 NOK | +2,73%

2024-08-23 08:00:00 Lytix Biopharma: Invitation to Q2 2024 Results Presentation 11,30 NOK | +2,73%

2024-08-14 13:44:42 Lytix Biopharma AS: PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy 11,35 NOK | +3,65%

2024-08-14 13:37:28 Lytix Biopharma: Foreløpige hovedresultater fra fase II-studie i pasienter med hudkrefttypen basalcellekarsinom viser 86 % total reduksjon i svulststørrelse, fullstendig fjerning av svulstene i halvparten av pasientene og potensial som førstelinjeterapi 11,35 NOK | +3,65%

2024-08-14 13:37:28 Lytix Biopharma AS: Phase II preliminary results from skin cancer (BCC) clinical trial show an 86 percent overall reduction of tumor size, complete clearance in half of the patients and the potential to be utilized as a first-line therapy 11,35 NOK | +3,65%

2024-08-06 16:51:14 Lytix Biopharma AS: Lytix Biopharma: Lytix's licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14 11,10 NOK | +12,58%

2024-08-06 16:38:13 Lytix Biopharma AS: Lytix's licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from part 2 of their Phase II trial of LTX-315 for the treatment of the skin cancer disease basal cell carcinoma on August 14, 2024 11,10 NOK | +12,58%

2024-08-06 16:38:13 Lytix Biopharma AS: Lytix' lisensieringspartner Verrica Pharmaceuticals publiserer foreløpige hovedresultater fra del 2 av deres fase II-studie av LTX-315 i hudkreftsykdommen basalcellekarsinom onsdag 14. august 2024 11,10 NOK | +12,58%

2024-05-30 07:03:37 Lytix Biopharma AS: Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones 6,30 NOK | +14,55%

2024-05-30 07:01:12 Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones 6,30 NOK | +14,55%

2024-05-22 11:47:39 Lytix Biopharma AS: Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024 5,40 NOK | 0,00%

2024-05-22 11:47:12 Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024 5,40 NOK | 0,00%

2024-05-14 14:29:52 Lytix Biopharma AS: Lytix Biopharma - Minutes of Ordinary General Meeting 6,10 NOK | +5,90%

2024-05-14 14:28:19 Lytix Biopharma - Minutes of Ordinary General Meeting 6,10 NOK | +5,90%

2024-05-13 15:16:23 Lytix Biopharma AS - New share capital registered 5,76 NOK | +5,11%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Lytix Biopharma

Kalender

Beskrivning

Lytix Biopharma

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden